Reviewer's report

Title: Insulin analogues dosing and costs - comparing real-life daily doses of insulin Detemir and insulin Glargine in type 2 diabetes patients

Version: 2 Date: 20 August 2012

Reviewer: Bruce W Bode

Reviewer's report:

Over 500 Type 2 DM patients from Denmark taking once daily insulin glargine or once daily insulin detemir were analyzed via a provider questionnaire on the units of insulin used per day as well as A1C, body weight and other factors. Methodology, statistics, presentation of results and conclusions as well as limitations are discussed appropriately. Analysis of the patients taking 2 shots of basal per day was not done but would have been worthwhile to determine if there were significantly more patients on detemir on two shots per day than glargine and thus units of detemir could be higher when used clinically.

No major revisions seen. Would be consistent in capitalizing or not capitalizing the "i" of insulin and the "g" and "d" of glargine and detemir in the manuscript.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I am on the speaker's bureau and am a consultant to Novo Nordisk, Lilly, and Sanofi.